Clinical trial HOVON-177 AML
Randomized study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy
| Cancers | |
|---|---|
| Organ | Acute leukemia |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Oui |
| Sponsor | Hovon |
| EudraCT Identifier | 2024-512733-32-00 |
| Last update |